Results 161 to 170 of about 2,669,966 (249)

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. [PDF]

open access: yesHepatology, 2018
Liu M   +12 more
europepmc   +1 more source

Reversal of refractory epilepsy in an adult with GAMT deficiency: A case report and comparative literature review

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive creatine biosynthesis disorder. Reports specifically focusing on adult patients remain scarce. Methods We report a 52‐year‐old female (the oldest documented case of GAMT deficiency to date) presenting with severe intellectual disability, refractory ...
Wei‐Hung Sung   +3 more
wiley   +1 more source

A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. [PDF]

open access: yesCancer, 2019
Gaillard SL   +10 more
europepmc   +1 more source

Vaginal host–microbe signatures linked to placental outcomes in mares

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Ascending placentitis is a leading cause of late‐term pregnancy loss in mares. Although pathogens are presumed to ascend from the caudal reproductive tract, the association between the vaginal microbiome and placentitis has not been systematically examined.
Machteld van Heule   +7 more
wiley   +1 more source

Metabolic Nanomedicine Reprograms Mesenchymal Stem Cells for Durable Exosome‐Mediated Immunomodulation

open access: yesExploration, EarlyView.
Prolonged inflammatory stress depletes NAD+ in mesenchymal stem cells, driving functional exhaustion and weakening their survival and immune‐regulating activity. We developed an NAD+‐delivering nanomedicine that restores cellular metabolism and improves therapeutic efficacy in colitis.
Jinfeng Chen   +9 more
wiley   +1 more source

Illuminating point‐of‐care diagnostics with aggregation‐induced emission biosensors

open access: yesFlexMat, EarlyView.
This review highlights the application of aggregation‐induced emission luminogens (AIEgens) in point‐of‐care (POC) diagnostics for disease biomarker detection. It systematically examines a range of biosensing platforms, including lateral flow immunoassays, microfluidic chips, and electrochemiluminescence sensors, alongside their utility in detecting ...
Danni Hu   +3 more
wiley   +1 more source

High‐Grade B‐Cell Lymphoma With 11q Aberration in Africa: A Differential Diagnosis in Cases With Features of Endemic Burkitt Lymphoma

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Fifty years ago, Zech et al. in this journal described for the first time the t(8;14) as a recurrent chromosomal aberration in Burkitt lymphoma (BL). Nevertheless, in regions where BL is not endemic, a subset of lymphomas with features of BL lacks the t(8;14)/IG::MYC and instead represents high‐grade B‐cell lymphoma with 11q aberration (HGBCL ...
Timothy Onyuma   +23 more
wiley   +1 more source

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

open access: yesiNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy